Literature DB >> 18487845

Inflammatory aspects of Alzheimer disease and other neurodegenerative disorders.

Claudia Schwab1, Patrick L McGeer.   

Abstract

Alzheimer and a number of other neurodegenerative diseases are characterized by the presence of reactive microglia and reactive astrocytes in association with the lesions. The classic view that microglia exist primarily in either a resting or activated state needs to be broadened in view of recent results. Resting microglia are in constant activity sampling their surround. Activated microglia may be pro-inflammatory, releasing inflammatory cytokines and other inflammatory mediators, or anti-inflammatory, promoting the healing process. There is evidence that microglial phagocytosis is more powerful in the anti-inflammatory state. Activated astrocytes also have pro-inflammatory and anti-inflammatory properties. In the pro-inflammatory state they release inflammatory cytokines. In the anti-inflammatory state they release various growth factors. In AD and other neurodegenerative diseases, both microglia and astrocytes are in a pro-inflammatory state. From a therapeutic point of view it is desirable to find methods of tipping the balance towards an anti-inflammatory state for both types of glia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18487845     DOI: 10.3233/jad-2008-13402

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  72 in total

1.  SOD1 (copper/zinc superoxide dismutase) deficiency drives amyloid β protein oligomerization and memory loss in mouse model of Alzheimer disease.

Authors:  Kazuma Murakami; Nakaba Murata; Yoshihiro Noda; Shoichi Tahara; Takao Kaneko; Noriaki Kinoshita; Hiroyuki Hatsuta; Shigeo Murayama; Kevin J Barnham; Kazuhiro Irie; Takuji Shirasawa; Takahiko Shimizu
Journal:  J Biol Chem       Date:  2011-11-09       Impact factor: 5.157

2.  Inflammation in neuroviral diseases.

Authors:  Pascale Giraudon; Arlette Bernard
Journal:  J Neural Transm (Vienna)       Date:  2010-08       Impact factor: 3.575

3.  Phosphatidylinositol 4-phosphate 5-kinase alpha is induced in ganglioside-stimulated brain astrocytes and contributes to inflammatory responses.

Authors:  Sang Yoon Lee; Bokyung Kim; Sarah Yoon; Yeon Joo Kim; Tian Liu; Joo Hong Woo; Yong-Joon Chwae; Eun-hye Joe; Ilo Jou
Journal:  Exp Mol Med       Date:  2010-09-30       Impact factor: 8.718

Review 4.  Long-term control of neuropathic pain in a non-viral gene therapy paradigm.

Authors:  E M Sloane; R G Soderquist; S F Maier; M J Mahoney; L R Watkins; E D Milligan
Journal:  Gene Ther       Date:  2009-03-05       Impact factor: 5.250

Review 5.  The multifaceted profile of activated microglia.

Authors:  Marina A Lynch
Journal:  Mol Neurobiol       Date:  2009-07-23       Impact factor: 5.590

6.  Expression profiles of cytokines in the brains of Alzheimer's disease (AD) patients compared to the brains of non-demented patients with and without increasing AD pathology.

Authors:  Kaori Morimoto; Juri Horio; Haruhisa Satoh; Lucia Sue; Thomas Beach; Seizaburo Arita; Ikuo Tooyama; Yoshihiro Konishi
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

Review 7.  LXR agonists: new potential therapeutic drug for neurodegenerative diseases.

Authors:  Pei Xu; Dabing Li; Xiaotong Tang; Xiaohang Bao; Jing Huang; Yongping Tang; Yang Yang; Haiwei Xu; Xiaotang Fan
Journal:  Mol Neurobiol       Date:  2013-04-27       Impact factor: 5.590

8.  Taxifolin prevents β-amyloid-induced impairments of synaptic formation and deficits of memory via the inhibition of cytosolic phospholipase A2/prostaglandin E2 content.

Authors:  Yuanyuan Wang; Qinwen Wang; Xiaoming Bao; Yanfei Ding; Jieyi Shentu; Wei Cui; Xiaowei Chen; Xiaofei Wei; Shujun Xu
Journal:  Metab Brain Dis       Date:  2018-03-14       Impact factor: 3.584

Review 9.  Towards retinoid therapy for Alzheimer's disease.

Authors:  K Shudo; H Fukasawa; M Nakagomi; N Yamagata
Journal:  Curr Alzheimer Res       Date:  2009-06       Impact factor: 3.498

10.  Serum levels of S100B and NSE proteins in Alzheimer's disease patients.

Authors:  Márcia L Chaves; Ana L Camozzato; Eduardo D Ferreira; Isabel Piazenski; Renata Kochhann; Oscar Dall'Igna; Guilherme S Mazzini; Diogo O Souza; Luis V Portela
Journal:  J Neuroinflammation       Date:  2010-01-27       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.